Amarex, an NSF International Company, Executes Five Rush COVID-19 Related Submissions to FDA
April 03, 2020
April 03, 2020
GERMANTOWN, Maryland, April 3 -- NSF International issued the following news release:
* * *
- Submissions include an IND, IND Amendment and Compassionate Use Approval for CytoDyn's product Leronlimab, a Compassionate Use Approval for a treatment device, and an EUA for a PCR-based IVD for COVID-19 detection
* * *
In early March 2020, Amarex Clinical Research LLC, an NSF International company, executed a rush submission of an emergency use Invest . . .
* * *
- Submissions include an IND, IND Amendment and Compassionate Use Approval for CytoDyn's product Leronlimab, a Compassionate Use Approval for a treatment device, and an EUA for a PCR-based IVD for COVID-19 detection
* * *
In early March 2020, Amarex Clinical Research LLC, an NSF International company, executed a rush submission of an emergency use Invest . . .